Effects of Sitagliptin (Januvia®) on Blood Glucose Control in Patients With Type 1 Diabetes
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01227460 |
|
Recruitment Status :
Completed
First Posted : October 25, 2010
Last Update Posted : May 21, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This is a multi-center, prospective, randomized, double-blind, parallel, placebo controlled clinical trial evaluating the efficacy of sitagliptin in suppressing glucagon release in subjects with type 1 diabetes over a 16 week treatment period. The hypothesis of this study is that sitagliptin (Januvia™) will decrease post-prandial glucagon release and may result in improved glucose control in adult patients with type 1 diabetes. There is only one small, pilot study of sitagliptin in patients with type 1 diabetes which significantly reduced total daily insulin dose and A1c values while improving mean blood glucose (MBG) and time spent in euglycemic range (1). In the pilot study, GLP-1 and glucagon levels were not assessed. The purpose of this trial is to determine if sitagliptin can suppress the paradoxical rise of glucagon, and thus can decrease A1c.
This study will enroll a maximum of 140 patients (with an expected 10% dropout rate) with A1c values between 7.5-10% who will be randomized in a 1:1 fashion to either the study drug or placebo. 100 of these patients will wear a continuous glucose monitor. Subjects may be using insulin via continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI). The clinic visits will be conducted at screening, -1 week, baseline/randomization, 4 weeks, 12 weeks, and 16 weeks in addition to telephone visits (Appendix 1 and 2). At home, starting at week 0 (randomization/baseline), subjects will take 100 mg/day of sitagliptin or placebo and continue for the study duration. Laboratory analysis will be performed at various time points assessing glucagon, A1c, C-peptide, glucagon-like-peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and insulin levels.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Type 1 Diabetes | Drug: Sitagliptin Drug: Sugar Pill | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 140 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Supportive Care |
| Official Title: | Effects of Sitagliptin (Januvia®) on Blood Glucose Control in Patients With Type 1 Diabetes and CGM Substudy of the Investigator Initiated Study Protocol Effects of Sitagliptin (Januvia) on Glucagon Suppression and GLP-1 Levels in Patients With Type 1 Diabetes; CGM Substudy |
| Study Start Date : | November 2010 |
| Actual Primary Completion Date : | July 2011 |
| Actual Study Completion Date : | July 2011 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: Sitagliptin |
Drug: Sitagliptin
pill/tablet form of 100mg each. will take one tablet a day throughout study |
| Placebo Comparator: Sugar Pill |
Drug: Sugar Pill
100mg tablet once a day |
- To demonstrate a decrease in post-prandial glucagon release as assessed by glucagon area under the curve (AUC) for 3 hours during 4 hour meal tolerance tests [ Time Frame: Primary outcome meausre will be recoreded after 16 weeks of treatment ]To demonstrate a decrease in post-prandial glucagon release as assessed by glucagon area under the curve (AUC) for 3 hours during 4 hour meal tolerance tests
- Secondary objectives: 1. To demonstrate a 0.3% decrease in A1c in patients with type 1 diabetes after 16 weeks of treatment with sitagliptin. 2. To evaluate changes in total, basal and bolus insulin dose while on sitagliptin. [ Time Frame: Secondary outcome meausre will be recoreded after 16 weeks of treatment ]
Secondary objectives:
- To demonstrate a 0.3% decrease in A1c in patients with type 1 diabetes after 16 weeks of treatment with sitagliptin.
- To evaluate changes in total, basal and bolus insulin dose while on sitagliptin.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Signed informed consent before any study-related activities
- Male or female aged 18 to 70 years
- Type 1 diabetes mellitus duration > 1 year
- Treatment with MDI or CSII therapy for at least 3 months prior to screening visit; stable insulin dose for the last 1 month
- No use of pramlintide, saxagliptin, metformin or sitagliptin for 1 month prior to enrollment
- A1c 7.5-10%
- Willingness to routinely practice at least 2-4 blood glucose measurements per day
- BMI ≤ 35 kg/m2
- Ability and willingness to adhere to the protocol including daily oral dose of study drug or placebo and week-long CGM wear
- Willing to complete phone and clinic visits
- Ability to speak, read and write English
Exclusion Criteria:
- Use of oral, inhaled or pre-mixed insulin
- Pregnant or intention to become pregnant during the course of the study not using adequate birth control methods
- Severe unexplained hypoglycemia requiring emergency treatment in the previous 3 months
- Use of systemic or inhaled corticosteroids
- History of hemoglobinopathies
- Diagnosis of anemia
- Post-renal transplantation, currently undergoing dialysis, creatinine >2.0 mg/dl or a calculated creatinine clearance of <50 mL/min
- Advanced retinopathy needing laser procedure or vitrectomy
- History of pancreatitis
- Extensive skin changes/diseases that inhibit wearing a sensor on normal skin
- Known allergy to adhesives
- Known allergy to study medication
- Participation in another investigational study protocol within 30 days prior to enrollment
- Any other condition, as determined by the investigator, which could make the subject unsuitable for the trial, impairs the subject's suitability for the trial, or impairs the validity of the informed consent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01227460
| United States, Colorado | |
| University of Colorado/Barbara Davis Center for Diabetes | |
| Aurora, Colorado, United States, 80045 | |
| Principal Investigator: | Satish K Garg, MD | University of Colorado Denver, Barbara Davis Center |
| Responsible Party: | Satish K. Garg, Professor of Medicine and Pediatrics, University of Colorado Denver School of Medicine Barbara Davis Center |
| ClinicalTrials.gov Identifier: | NCT01227460 |
| Other Study ID Numbers: |
MRK-SI-100 |
| First Posted: | October 25, 2010 Key Record Dates |
| Last Update Posted: | May 21, 2014 |
| Last Verified: | May 2014 |
|
Type 1 diabetes, Sitagliptin |
|
Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune Diseases Immune System Diseases Sitagliptin Phosphate Hypoglycemic Agents |
Physiological Effects of Drugs Incretins Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Dipeptidyl-Peptidase IV Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |